Salomao R, Rigato O, Pignatari A, Freudenberg M, Galanos C
Infection. 1999; 27(1):1-11.
PMID: 10027099
DOI: 10.1007/BF02565163.
Rello J, Ricart M, Mirelis B, Quintana E, Gurgui M, Net A
Intensive Care Med. 1994; 20(2):94-8.
PMID: 8201105
DOI: 10.1007/BF01707661.
Clumeck N, George C
Intensive Care Med. 1981; 7(3):109-14.
PMID: 7012215
DOI: 10.1007/BF01738612.
Appelbaum P, Schick S, Kellogg J
J Clin Microbiol. 1980; 12(4):533-7.
PMID: 6999020
PMC: 273630.
DOI: 10.1128/jcm.12.4.533-537.1980.
Fujinaga Y, Taniyama K
Jpn J Surg. 1981; 11(2):100-4.
PMID: 6895392
DOI: 10.1007/BF02468877.
Septicaemia in a medical intensive care unit. Clinical, biochemical and microbiological data of 109 cases.
Dominguez de Villota E, Algora A, Rubio J, Roig M, Mosquera J, Galdos P
Intensive Care Med. 1983; 9(3):109-15.
PMID: 6345627
DOI: 10.1007/BF01772576.
Pyocin typing of Pseudomonas aeruginosa: a simplified method.
Jones L, Zakanycz J, Thomas E, Farmer 3rd J
Appl Microbiol. 1974; 27(2):400-6.
PMID: 4207282
PMC: 380042.
DOI: 10.1128/am.27.2.400-406.1974.
Characterization of murine monoclonal antibodies to Escherichia coli J5.
Miner K, Manyak C, Williams E, Jackson J, Jewell M, Gammon M
Infect Immun. 1986; 52(1):56-62.
PMID: 3514463
PMC: 262197.
DOI: 10.1128/iai.52.1.56-62.1986.
Prognostic indicators of septicaemia--a two year prospective evaluation.
Iyer R, Duckett G, BROGAN T, TWEEDY P, Sharpe T
Postgrad Med J. 1987; 63(746):1049-53.
PMID: 3451232
PMC: 2428588.
DOI: 10.1136/pgmj.63.746.1049.
Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.
Dunn D
World J Surg. 1987; 11(2):233-40.
PMID: 3296482
DOI: 10.1007/BF01656407.
Administration in vivo of recombinant interleukin 2 protects mice against septic death.
Weyand C, Goronzy J, Fathman C, OHanley P
J Clin Invest. 1987; 79(6):1756-63.
PMID: 3294901
PMC: 424518.
DOI: 10.1172/JCI113016.
Correlation between electrophoretic types B1 and B2 of carboxylesterase B and host-dependent factors in Escherichia coli septicaemia.
Picard B, GOULLET P
Epidemiol Infect. 1988; 100(1):51-61.
PMID: 3276540
PMC: 2249197.
DOI: 10.1017/s0950268800065559.
Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.
Fantin B, Leggett J, Ebert S, Craig W
Antimicrob Agents Chemother. 1991; 35(7):1413-22.
PMID: 1929302
PMC: 245182.
DOI: 10.1128/AAC.35.7.1413.
History of recognition and measurement of colonization resistance of the digestive tract as an introduction to selective gastrointestinal decontamination.
Van Der Waaij D
Epidemiol Infect. 1992; 109(3):315-26.
PMID: 1468517
PMC: 2271937.
DOI: 10.1017/s0950268800050317.
Functional role of antibody against "core" glycolipid of Enterobacteriaceae.
Young L, Stevens P, Ingram J
J Clin Invest. 1975; 56(4):850-61.
PMID: 1099119
PMC: 301940.
DOI: 10.1172/JCI108164.
Antibiotics and endotoxic shock.
McCabe W
Bull N Y Acad Med. 1975; 51(9):1084-95.
PMID: 1058731
PMC: 1749600.
Epidemiology of Pseudomonas aeruginosa in a general hospital: a four-year study.
Thomas E, Jones L, Simao E, SOLE-VERNIN C, Farmer 3rd J
J Clin Microbiol. 1975; 2(5):397-402.
PMID: 811684
PMC: 274198.
DOI: 10.1128/jcm.2.5.397-402.1975.
In vitro activity of gentamicin, amikacin and netilmicin alone and in combination with carbenicillin against Serratia marcescens.
Pogwizd S, Lerner S
Antimicrob Agents Chemother. 1976; 10(6):878-84.
PMID: 795373
PMC: 429858.
DOI: 10.1128/AAC.10.6.878.
In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.
Fu K, Neu H
Antimicrob Agents Chemother. 1976; 10(3):511-8.
PMID: 791104
PMC: 429781.
DOI: 10.1128/AAC.10.3.511.
Relation between the faecal concentration of various potentially pathogenic microorganisms and infections in individuals (mice) with severely decreased resistance to infection.
Van Der Waaij D
Antonie Van Leeuwenhoek. 1978; 44(3-4):395-405.
PMID: 582244
DOI: 10.1007/BF00394316.
